[肺动脉高压与右心室衰竭。第十一章。内皮素受体阻滞剂治疗原发性肺动脉高压]

[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].

作者信息

Batyraliev T A, Makhmutkhodzhaev S A, Ekinsi E, Pataraia S A, Pershukov I V, Sidorenko B A, Preobrazhenskiĭ D V

出版信息

Kardiologiia. 2007;47(7):73-82.

Abstract

In a series of articles the authors discuss literature data concerning epidemiology of pulmonary arterial hypertension (PAH), its current classification; peculiarities of its pathogenesis and treatment in various diseases and conditions. In the eleventh communication the authors discuss literature data related to the role of endothelin system in pathogenesis of primary (idiopathic) PAH, as well as PAH associated with diffuse diseases of connective tissue and congenital heart disease. This communication also contains presentation of clinical pharmacology of three available endothelin receptor blockers - bosentan, sitaxsentan, ambrisentan, and analysis of results of randomized controlled trials of efficacy and safety of these agents in patients with idiopathic PAH and PAH associated with diffuse diseases of connective tissue and congenital heart disease.

摘要

在一系列文章中，作者们讨论了有关肺动脉高压（PAH）流行病学的文献数据、其当前分类；在各种疾病和病症中其发病机制及治疗的特点。在第十一次交流中，作者们讨论了与内皮素系统在原发性（特发性）PAH发病机制中的作用相关的文献数据，以及与结缔组织弥漫性疾病和先天性心脏病相关的PAH。本次交流还介绍了三种可用的内皮素受体阻滞剂——波生坦、西他生坦、安立生坦的临床药理学，并分析了这些药物在特发性PAH以及与结缔组织弥漫性疾病和先天性心脏病相关的PAH患者中进行的疗效和安全性随机对照试验的结果。